<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365506</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-394-1658</org_study_id>
    <secondary_id>2015-002413-30</secondary_id>
    <nct_id>NCT02365506</nct_id>
  </id_info>
  <brief_title>Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome</brief_title>
  <official_title>A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of oral eleclazine (GS-6615) on QTc interval, safety, and
      tolerability in adults with long QT2 syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)</measure>
    <time_frame>Up to 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in daily QT interval</measure>
    <time_frame>Up to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal QT shortening</measure>
    <time_frame>Up to 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>LQT2 Syndrome</condition>
  <arm_group>
    <arm_group_label>Eleclazine Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eleclazine dose level 1 + placebo to match eleclazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eleclazine Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eleclazine dose level 2 + placebo to match eleclazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match eleclazine for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eleclazine</intervention_name>
    <description>Eleclazine tablets administered orally</description>
    <arm_group_label>Eleclazine Dose Level 1</arm_group_label>
    <arm_group_label>Eleclazine Dose Level 2</arm_group_label>
    <other_name>GS-6615</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match eleclazine tablets administered orally</description>
    <arm_group_label>Eleclazine Dose Level 1</arm_group_label>
    <arm_group_label>Eleclazine Dose Level 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with an established diagnosis of LQT2 (by genotype testing)

          -  Mean (of triplicate) QTc interval ≥ 480 msec for at least four out of seven time
             points, determined by standard 12-lead ECG, at screening

        Exclusion Criteria:

          -  Known mutations associated with LQT1 or LQT3

          -  Known or suspected history of seizures or epilepsy

          -  History of heart failure defined as New York Heart Association (NYHA) Class IV and/or
             known left ventricular ejection fraction (EF) ≤ 45%

          -  Body mass index (BMI) ≥ 36 kg/m^2 at screening

          -  Severe renal impairment at screening (defined as an estimated glomerular filtration
             rate (eGFR) &lt; 30 mL/min/1.73m^2, using the 4 Variable Modification of Diet in Renal
             Disease (MDRD) equation), as determined by the study center

          -  Abnormal liver function tests at screening, defined as alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) &gt; 2 x upper limit of normal (ULN), or total
             bilirubin &gt; 1.5 x ULN

          -  An aborted cardiac arrest (ACA), implantable cardioverter-defibrillator (ICD)
             implantation, syncopal episode, or appropriate ICD therapy within 3 months prior to
             screening

          -  Any other condition or circumstance that in the opinion of the investigator would
             preclude compliance with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Hellawell, MD, FACC</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center/Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital Long QT Syndrome</keyword>
  <keyword>LQTS</keyword>
  <keyword>Long QT2 Syndrome</keyword>
  <keyword>LQT2</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

